GB2157283A

GB2157283A - Esters of 3,5-diacetylamino-2,4,6-triiodobenzoic acid as X-ray contrast agents

Info

Publication number: GB2157283A
Application number: GB08408251A
Authority: GB
Inventors: Isabel Charles; Malcolm L Robinson
Original assignee: ER Squibb and Sons LLC
Current assignee: ER Squibb and Sons LLC
Priority date: 1984-03-30
Filing date: 1984-03-30
Publication date: 1985-10-23
Also published as: GB2157283B; GB8408251D0

Abstract

New X-ray contrast agents are provided which are esters of diatrizoic acid having the structure <IMAGE> wherein R is an alkyl group of 10 to 22 carbons or a group of the structure <IMAGE> wherein R<1> is an alkyl group of 2 to 15 carbons. X-ray contrast medium containing the above X-ray contrast agent and a carrier therefor such as a liposome carrier.

Description

SPECIFICATION X-ray contrast agents Field of the invention The present invention relates to esters of diatrizoic acid which are useful as contrast agents, to X-ray contrast media containing such contrast agents, which may include a liposome carrier, and to a method of using the above X-ray contrast media in the X-ray visualization of body cavities and organs.

Background of the invention The use of certain iodine-containing benzoic acid derivatives as X-ray contrast agents is well known. For example, U.S. Patent No. 4,018,783 to Soulal discloses X-ray contrast agents which are of the structure

wherein A is -CONHCH3 or -N(CH3)COCH3 and R is a phthalide group or lower alkyl optionally substituted with an aryl or dialkylamino group, or with a group of the formula -OCOR1 wherein R1 is lower alkyl, except that when A is -CONHCH3, then R is not acetoxymethyl or pivaloyloxymethyl.

British Patent 866,184 discloses triiodobenzoic acid derivatives of the structure

wherein R1is H or lower alkyl; R2 is H or lower alkanoyl; R3 is H or lower alkanoylamino.

U. S. Patent No. 3,128,301 discloses 3,5-diacylamino-2, 4, 6,-triiodobenzoic acid esters of the structure

wherein R is lower alkyl, and R1 and R2 are lower alkanoyl.

U. S. Patent No. 4,192,859 to Mackaness et al discloses the use of liposomes as carriers for contrast agents such as diatrizoic acid, sodium diatrizoate and other iodinated contrast agents.

Havron et al in "Radiopaque Liposomes: A Promising New Contrast Material for Computed Tomography of the Spleen", Radiology 140:507-511, August, 1981, disclose radiopaque positively charged liposomes as carriers for diatrizoate meglumine and diatrizoate sodium (Renografin) for use in computed tomography of the spleen.

Ryan et al in "The Preparation and Characterization of Liposomes Containing X-Ray Contrast Agents," Biochemica et Biophysica Acta. 756(1983), 106-110 (Elsevier Biomedical Press) disclose use of Renografin and Hypaque (RTM) in liposomes in X-ray computed tomography.

Description ofthe invention In accordance with the present invention, new X-ray contrast agents are provided having the formula I

wherein R is an alkyl contains 10 to 22 carbons, and preferably 14 to 20 carbons, or a group of the structure

wherein R1 is an alkyl group of 2 to 15 carbons, and preferably 4 to 12 carbons.

Thus, the compounds of formula I of the invention cover compounds of the following structures

Further in accordance with the present invention, there is provided an X-ray contrast media composition which includes a compound of formula I together with a suitable pharmaceutically acceptable carrier therefor.

The term "alkyl" as employed herein includes both straight and branched chain radicals of 10 to 22 carbons, preferably 14 to 20 carbons in the case of R, and 2 to 15 carbons, preferably 4 to 12 carbons, in the case of R1. Examples of suitable R and R1 alkyl groups include, but are not limited to decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, septadecyl, octadecyl, nonadecyl, eicosanyl, heneicosanyl, and docosanyl, and including the various branched chain-isomers thereof.

The esters of diatrizoic acid of the invention may be prepared by using conventional esterification techniques. For example, in preparing the long chain esters of formula IA, diatrizoic acid of structure A TAKE IN HERE

is reacted with an appropriate alcohol of structure B ROH B In a preferred process, diatrizoic acid is reacted with an alkali metal hydroxide such as KOH or NaOH to form the corresponding alkali metal diatrizoate which in turn, is reacted with an alkyl halide of the structure C RX C wherein X is Br, Cl or I, in the presence of an inert organic solvent such as acetone, dimethyl formamide and an alkali metal iodide such as KI.

Compounds of formula IB may be prepared by reacting diatrizoic acid with an aqueous alkali metal hydroxide such as KOH or NaOH to form the corresponding salt. A solution of the diatrizoate salt in water is then treated with a tetraalkylammonium halide, for example, benzyltributylammonium chloride, in the presence of a water immiscible organic solvent, such as chloroform, dichloromethane ortoluene. A halomethyl ester of the structure D is added

(where X is Cl or Br) D and the mixture is allowed to react for 1 to 16 days to form IB.

The X-ray contrast medium of the invention which includes an X-ray contrast agent of the invention and a pharmaceutically acceptable carrier therefor, may be used in X-raying and scanning body cavities and organs.

In a more preferred embodiment of the invention, the X-ray contrast agent of formula I is incorporated in a liposome carrier employing procedures as described in U.S. Patent No.4,192,859 and as such is especially useful in lymphographictechniques.

The X-ray contrast agent of the invention will be present in the liposome contrast medium in an amount within the range of from about 20 to about 60% by weight of the contrast medium, and preferably from about 30 to about 50% by weight of the contrast medium, depending upon the desired concentration of iodine.

The liposomes and preparations for same suitable for use herein include those disclosed in U. S. Patent No.3,957,971 to Oleniacz; G Sessa et al, J. Lipid Res., Vol.9,310 (1968), as well as in the various references discussed hereinbefore, and other liposomes known in the art.

Liposomes employed in the present invention generally comprise lipid materials, predominantly of the phospholiped type (for example, a sterol), lecithin, dicetyl phosphate, or stearylamine, in an organic solvent.

When employing an X-ray contrast medium containing an X-ray contrast agent and a liposome carrier therefor, according to the invention, the X-ray contrast medium is administered to the body of the test object wherafterthe body is exposed to X-rays and photographs may be taken or the image observed directly on a fluorescent screen, or other X-ray techniques may be applied in a conventional manner. The dose of contrast medium administered is selected according to the category of the investigation, so that a sufficient contrast effect is obtained.

The test object may include mammalian species, such as humans, dogs, cats, monkeys, sheep, pigs, horses, bovine animals and the like.

As indicated, the X-ray contrast medium of the invention is particularly suitable for use in lymphography.

However, the X-ray contrast medium may be employed for visualizing many different body cavities and organs, such as the chest cavity including the bronchial tree, and the gastrointestinal tract. In the latter instance, the contrast medium is administered perorally as a thick liposomal formulation. The intestines can also be visualized by administering the X-ray contrast medium rectally in the form of a liposomal enema.

Another example is the visualization of blood vessels subsequent to the X-ray contrast medium being injected in the form of a sterile liposomal preparation. When injected intraveneously the X-ray contrast medium is excreted with the urine and enables visibilization of the renal pelvis, ureters and bladders. Further examples are the use of the X-ray contrast media in imaging the biliary system, hysterosalpingography, cholangiography, myelography, angiography, sialography, and liver and spleen imaging.

As indicated, the X-ray contrast agent of the invention may be combined with a pharmaceutically acceptable carrier (other than liposomes) depending upon the particular use of the final composition which may be employed for diagnostic purposes in bronchography, the delineation of tissue planes, salpinography and transumbilical heptography. In such applications, the X-ray contrast agents of the invention may be administered as an aqueous dispersion, an aerosol, in microencapsulated form or in an oily solution. Thus, for bronchography, the X-ray contrast agent of the invention may be combined with a non-toxic water-insoluble or metabolizable solid carrier, such as lactose, for purpose of insufflation.

The following Examples represent preferred embodiments of the present invention.

EXAMPLE 1 Octadecyl diatrizoate A solution of potassium hydroxide (5.36 g of 85% purity) in water (17 ml) was added to diatrizoic acid (50 9), followed by acetone (300 mi), 1-bromooctadecane (30 g) and potassium iodide (5 g). The suspension was stirred and heated at 56"C (under reflux) for 10 days. The insoluble material was collected by filtration and washed with ethyl acetate. The solid was then extracted with hot (600C) methanol-chloroform (1:1) and the solution obtained was filtered and concentrated to give octadecyl diatrizoate, which was recrystallized from 1:1 methanol :chloroform. The white solid had a m.p. 248-250"C(d).

EXAMPLE 2 Pivaloyloxymethyl diatrizoate Aqueous N sodium hydroxide (33 ml) was added to a stirred suspension of diatrizoic acid (20 g) in water (20 ml), followed by benzyltributylammonium chloride (10.2 g), chloroform (55 ml) and chloromethyl pivalate (5 ml). The reaction mixture was stirred vigorously at room temperature for 2 weeks. The precipitated solid was collected by filtration and recrystallized from methanolchloroform, affording the pivaloyloxymethyl diatrizoate as white crystals, m.p. 253-254.5"C(d).

EXAMPLE 3 Nonadecyl diatrizoate Following the procedure of Example 1 except substituting 1-bromononadecane for 1-bromooctadecane, the title compound is obtained.

EXAMPLE 4 Septadecyl diatrizoate Following the procedure of Example 1 except substituting 1-bromoseptadecane for 1-bromooctadecane, the title compound is obtained.

EXAMPLE 5 Pentadecyl diatrizoate Following the procedure of Example 1 except substituting 1-bromopentadecane for 1 -bromooctadecane, the title compound is obtained.

EXAMPLE 6 Dodecyl diatrizoate Following the procedure of Example 1 except substituting 1-bromododecane for 1-bromooctadecane, the title compound is obtained.

EXAMPLE 7 Eicosanyl diatrizoate Following the procedure of Example 1 except substituting 1-bromoeicosane for 1 -bromooctadecane, the title compound is obtained.

EXAMPLE 8 Docosanyl diatrizoate Following the procedure of Example 1 except substituting 1-bromodocosane for 1-bromooctadecane, the title compound is obtained.

EXAMPLE 9 Hexanoyloxymethyl diatrizoate Following the procedure of Example 2 except substituting chloromethyl hexanoate for chloromethyl pivalate, the title compound is obtained.

EXAMPLE 10 Valero yloxymeth yl diatrizoate Following the procedure of Example 2 except substituting chloromethyl valerate for chloromethyl pivalate, the title compound is obtained.

EXAMPLE 11 Octanoyloxymethyl diatrizoate Following the procedure of Example 2 except substituting chloromethyl octanoate for chloromethyl pivalate, the title compound is obtained.

EXAMPLE 12 Decanoyloxymethyl diatrizoate Following the procedure of Example 2 except substituting chloromethyl decanoate for chloromethyl pivalate, the title compound is obtained.

EXAMPLE 13 Propanoyloxymethyl diatrizoate Following the procedure of Example 2 except substituting chloromethyl propanoate for chloromethyl pivalate, the title compound is obtained.

EXAMPLE 14 Pentadecanoyloxymethyl diatrizoate Following the procedure of Example 2 except substituting chloromethyl pentadecanoate for chloromethyl pivalate, the title compound is obtained.

EXAMPLE 15 A quantity of each of 1.4 g egg lecithin (egg phosphotidyl choline) and 0.6 g cholesterol are dissolved in 20 ml of chloroform. The chloroform is evaporated leaving a film of neutral phospholipid residue. Two grams of the phospholipid is then added to 7 ml of neutral buffered solution containing 4 g of the X-ray contrast agent octadecyl diatrizoate prepared as described in Example 1. The mixture is stirred with a magnetic stirrer until a final homogeneous liposomal mixture is obtained. Ten milliliters of the final liposome preparation contains 4 g of the X-ray contrast agent.

The so-formed X-ray contrast medium may be employed as described in U. S. Patent No. 4,192,859.

EXAMPLE 16 Two grams of neutral phospholipid residue, prepared as described in Example 15, is added to 6.7 ml of neutral buffered solution containing 4 g of pivaloyloxymethyl diatrizoate. The mixture is stirred with a magnetic stirrer until a homogeneous liposomal mixture is obtained. Ten milliliters of the final liposome preparation contains 4 g of pivaloyloxymethyl diatrizoate.

The so-formed contrast medium may be employed as described in U. S. Patent No. 182,859.

EXAMPLE 17 An X-ray contrast composition is prepared by admixing octadecyl diatrizoate acid (10 g) and lactose (0.5 g).

EXAMPLE 18 An X-ray contrast composition is prepared by admixing pivaloyloxymethyl diatrizoate (10 g) and lactose (0.5 9).

Claims

1. An X-ray contrast agent having the structure TAKE IN HERE

wherein R is an alkyl group of from 10 to 22 carbons or a group of the structure 0 -CH20CR wherein R1 is an alkyl group of 2 to 15 carbons.

2. The compound as defined in Claim 1 wherein R is an alkyl group of 10 to 22 carbons.

3. The compound as defined in Claim 2 wherein R is an alkyl group of 14to 20 carbons.

4. The compound as defined in Claim 3 wherein R is octadecyl.

5. The compound as defined in Claim 1 wherein R is

6. The compound as defined in Claim 5 wherein R1 is an alkyl group of 4 to 12 carbons.

7. The compound as defined in Claim 6 wherein R1 is -C(CH3)3.

8. An X-ray contrast medium comprising an X-ray contrast agent as defined in Claim 1, 2,3,5 or 6 and a carrier therefor.

9. The X-ray contrast medium as defined in Claim 8 wherein said carrier is a liposome.

10. The X-ray contrast medium as defined in Claim 8 wherein said contrast agent is octadecyl diatrizoate.

11. The X-ray contrast medium as defined in Claim 8 wherein said contrast agent is pivaloyloxymethyl diatrizoate.

12. A method for the X-ray visualization of body cavities and organs, which comprises administering to the body of the test object an effective contrast producing amount of an X-ray contrast medium as defined in Claim 8 or 9.

13. The method as defined in Claim 12 wherein the liver is visualized.

14. The method as defined in Claim 12 wherein the spleen is visualized.

15. The method as defined in Claim 12 wherein the gall bladder is visualized.

16. The method as defined in Claim 12 wherein the spinal cord is visualized.

17. The method as defined in Claim 12 wherein the X-ray contrast agent employed is the octadecyl diatrizoate or pivaloyloxymethyl diatrizoate.

18. The method for X-ray visualization of lymphatic channels, which comprises administering to the body of the test object an efective contrast producing amount of an X-ray contrast medium as defined in Claim 9.

19. A method for the radiographic examination of the gastrointestinal tract, which comprises administering to the body of the test object an effective contrast producing amount of an X-ray contrast medium as defined in Claim 8.

20. A compound according to Claim 1, as named in any one of Examples 3 - 14.

21. An X-ray contrast medium according to Claim 8 substantially as described in any one of Examples 15-18.